RDC Peptide

The targeting ligands of RDC mainly include antibodies, peptides, and small molecules, etc. Peptides are of growing interest for use in radiopharmaceuticals largely due to their size, which has ramifications on stability, biological circulation, and synthesis. Peptide-radionuclide conjugate drugs can achieve ideal drug delivery, which combines the excellent tissue penetration and low immunogenicity of peptides to improve treatment efficiency and reduce side effects related to systemic toxicity. In recent years, a variety of peptide-radionuclide conjugate drugs have been approved by the FDA and are playing an increasingly important role in cancer diagnosis and treatment.